Scott Gottlieb is President Donald Trump’s choice to lead the agency, according to Bloomberg sources at the White House.
Gottlieb, a former deputy commissioner of the FDA under George W. Bush, will look to cut th red tape at the FDA, enabling the agency to approve drugs, particularly generic drugs, more quickly.
Before accepting the position, Gottlieb would have to to resign from the pharmaceutical boards, and get rid of stock in companies he’d regulate at FDA. Gottlieb also must be confirmed by the Senate before he takes over at the agency.
Read the Bloomberg coverage